Press Release

SCYNEXIS Announces Exclusive License Agreement With GSK for Brexafemme

April 4, 2023

Palo Alto – April 4, 2023 – Cooley advised SCYNEXIS on its exclusive license agreement with GSK for Brexafemme. Lawyers Marya Postner, Carly Robinson, Bin Wang, Barbara Borden, Rebecca Givner-Forbes, Matt Hemington and Brett White led the Cooley team.

The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp – a US Food and Drug Administration-approved antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC that it being sold as Brexafemme – and to develop it for additional indications, including the treatment of invasive candidiasis (IC), a life-threatening fungal infection. Under the terms of the agreement, SCYNEXIS will receive an upfront payment of $90 million from GSK, with additional potential milestone-based payments totaling $503 million. If specific development, regulatory and commercial milestones for the IC indication are completed, GSK will pay up to $245.5 million, with a further $15 million upon successful FDA approval of an additional indication. GSK also will pay up to $242.5 million in sales-related milestone payments if certain commercial performance metrics are achieved and mid-single digit to mid-teen digit tiered royalties on the net sale totals across all indications, with the top royalty tier based on achieving more than $1 billion in annual net sales.

SCYNEXIS is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists have been developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in community and hospital settings.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.